ライフサイエンスコーパス: mixed-type

1 s (i.e., IBS-Constipation, IBS-Diarrhea, IBS-Mixed Type).

2 nal groups (i.e., hydroxamate, catechol, and mixed type).

3 hydroxamate, alpha-hydroxyl-carboxylate, or mixed types).

4 Circumferential Type, Saber-Sheath Type, and Mixed Type.

5 eyes (14.3%) as type 2, and 1 eye (7.1%) as mixed type.

6 -2 and TG, the inhibition appeared to be the mixed type.

7 , and one met criteria for bipolar disorder, mixed type.

8 e and less frequently of the cholestatic and mixed types.

9 with MNV type 1 (26.5%), type 2 (29.1%), or mixed type 1 and 2 (34.6%).

10 given SBR alone, and these cells displayed a mixed type 1 and 2 (or Th0) pattern of cytokine expressi

11 ibuted as follows: type 1, 63%; type 2, 27%; mixed type 1 and 2, 3%; type 3, 3%; aneurysmal type 1, 3

12 eumonic plague vaccines should aim to induce mixed type 1 and type 17 cellular responses.

13 made as part of a type 0 cytokine response (mixed type 1 and type 2) and is required for normal deve

14 etween endotypes, notably that patients with mixed type 1 and type 3 inflammation demonstrate more re

15 Cluster 2 (4.5%) represented a mixed type 1/3 inflammatory endotype (IFN-gamma(High)/IL

16 ogic subtypes: type 1, low-grade type 2, and mixed type 1/low-grade type 2 tumors.

17 laining 69.50% of the variance, with type 2, mixed type 1/T(h)17-cell, growth factor, and neutrophil

18 es and were mediated by T cells displaying a mixed type 1/type 2 cytokine phenotype.

19 , whereas IL-10-deficient animals generate a mixed type 1/type 2 cytokine profile and show reduced pu

20 A mixed type 1/type 2 response of IFN-gamma-producing CD8(

21 e 1 bubbles (88.4%), 11 type 2 (9.8%), and 2 mixed-type (1.8%).

22 growth factors (A), type-2/3 cytokines (B), mixed type-1/2/3 cytokines (C), and chemokines (D) that

23 ection pulmonary (sputum) samples revealed a mixed type-1/type-2 inflammatory cytokine profile, whils

24 ss opacities and reticular patterns (32.2%), mixed type (13.6%), and white lungs (1.7%); common accom

25 endent proinflammatory gene expression and a mixed type 2/type 3 response in mice, which may be chara

26 independent risk factor for development of a mixed, type-2 dominant CRS inflammatory response.

27 imaging, 74 patients had MD-IPMN (14%), 205 mixed-type (40%), and 233 suspected BD-IPMN (46%).

28 s 3.7 months, with the majority of IHs being mixed type (57%) affecting the head and neck (81%).

29 ated with NH(2) and CH(3) SAMs were largely 'mixed type' (81% and 86%, respectively) commensurate wit

30 Notably, P4 exhibited potent mixed-type ACE-inhibition and bacteriostatic effects.

31 ease in the Vmax for phosphate, indicating a mixed type activation.

32 step, while glutamine provided nonessential mixed-type activation of the uridylyl-removing activity,

33 vided into four categories: fibrosis, pearl, mixed type and late-postoperative capsular bag distensio

34 Studying the molecular profiles of mixed-type and branch-duct (BD) intraductal papillary mu

35 n kinetics revealed that derivative 17b is a mixed-type and competitive inhibitor for TGK and TAO, re

36 analyses showed that cryptotanshinone was a mixed-type and irreversible inhibitor.

37 4%) glandular type breast patients, 39 (32%) mixed type, and 29 (23%) fatty type.

38 24 (35%) were surgical, and 20 (29%) were of mixed type, and 64 (93%) were located in teaching hospit

39 f MMP-7, MMP-9, and MT1-MMP by Brij-35 was a mixed type as determined by Dixon's plot; however, the i

40 rtion of eyes with any MNV type 3 (including mixed type) at baseline developed new MA at month 24 (49

41 arcinoma, three a type B3 thymoma, and two a mixed type B3 thymoma and thymic carcinoma.

42 mpounds indicated that majority of them were mixed-type BChE inhibitors.

43 Inferring dependencies between mixed-type biological traits while accounting for evolut

44 holangiocarcinoma revealed that combined and mixed type cHCC-ICCs are distinct subtypes with differen

45 eparate type cHCC-ICCs, whereas combined and mixed type cHCC-ICCs were all monoclonal origin.

46 Indicative of a mixed-type (combination of competitive and non-competiti

47 A Lineweaver-Burk plot indicates mixed-type competitive ligand binding between VPg and an

48 sis for wild type and mutant protease showed mixed-type competitive-uncompetitive inhibition for daru

49 , and immunohistochemical findings suggest a mixed-type, delayed hypersensitivity reaction as the mec

50 a (aSHR = 2.51, 95% CI, 1.01-6.25) and other/mixed-type dementia (aSHR = 5.58, 95% CI, 4.24-7.62) sub

51 The mixed type enzyme inhibition by peptides suggested that

52 were analyzed in 53 patients (33 cam- and 20 mixed-type FAI) and 53 age- and sex-matched asymptomatic

53 tial equations including elliptic-hyperbolic mixed type, free-boundary problems, and corner singulari

54 ntidiabetic agents that act as nonessential, mixed-type GK activators (GKAs) that increase the glucos

55 by subtype: Alzheimer's, vascular, and other/mixed-type), graft loss, and death using Fine and Gray's

56 lso induces antiparallel structure to form a mixed-type hybrid structure in Na(+) solution.

57 ocnemius and tibialis anterior muscles (with mixed type I and II fiber content), while a significant

58 ) were single-type infections, 9 (8.0%) were mixed-type infections with more than one G or P type, an

59 ver-Burk plots indicated that 5-CQA exerts a mixed type inhibition as km increased and Vmax decreased

60 Troglitazone exhibited a mixed type inhibition of ACS4.

61 analogues 3-OPP/OPP and 3-SPP/SPP displayed mixed type inhibition with KI = 1.4 muM and KI = 5.5 muM

62 rs were in the range of 0.5-56 muM, all with mixed type inhibition, predominantly competitive.

63 both free and nanoencapsulated, presented a mixed-type inhibition behavior, and encapsulated lutein

64 P competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase.

65 The two methods agreed showing mixed-type inhibition for monophenolase and diphenolase

66 COS-EGCG conjugate showed the mixed-type inhibition kinetic and had K(ic) of 1.516 mg/

67 The model suggests a mixed-type inhibition mechanism for Mg(2+) inhibition of

68 075 and 0.10 mM, respectively, and showing a mixed-type inhibition mode.

69 complex, ISIS 2302 demonstrated hyperbolic, mixed-type inhibition of chromogenic substrate cleavage

70 ISIS 2302 demonstrated hyperbolic, mixed-type inhibition of factor X activation by the intr

71 Our results provide insights into the mixed-type inhibition of GAT1 by tiagabine, which is an

72 tes acted as a random bireactant system with mixed-type inhibition of substrate binding by one substr

73 Mixed-type inhibition on rat maltase activity was observ

74 how that SLO-1 proceeds through a hyperbolic mixed-type inhibition pathway, where OS binding (K(i) =

75 ifluoromethylphenyl)acetamide (5), showed a mixed-type inhibition pattern, with a K(i) of 1.3 muM an

76 The compound exhibits mixed-type inhibition with respect to all three enzyme s

77 mechanism analogous to system C5 hyperbolic mixed-type inhibition with respect to erythrose-4-phosph

78 f factor IX activation was best described by mixed-type inhibition with the affinity of leupeptin and

79 ate larger inhibitory complexes resulting in mixed-type inhibition, in the presence of selenate and p

80 4 +/- 32 nM) was characterized by hyperbolic mixed-type inhibition, indicating that factor IX binds t

81 study indicates that fucoxanthin is showing mixed-type inhibition.

82 (0.075+/-0.010-0.103+/-0.017) mg/ml, also a mixed-type inhibition.

83 0.81+/-0.03mg/ml, respectively; both showed mixed-type inhibition.

84 ia PfCRT in a manner that is consistent with mixed-type inhibition.

85 petitive substrate inhibition and by GTP via mixed-type inhibition.

86 ults suggested that the inhibitor acted as a mixed type inhibitor by reducing both anodic and cathodi

87 CG was a competitive inhibitor of FabI and a mixed type inhibitor of FabG demonstrating that EGCG int

88 or versus ATP, whereas quercetin serves as a mixed type inhibitor versus ATP.

89 lyzed cleavage of allothreonine as a partial mixed type inhibitor, reducing both k(cat) and K(m) by 4

90 o IRF3 phosphorylation, SIKE functioned as a mixed-type inhibitor (K(i, app) = 350 nM) rather than, g

91 tudies showed that 10-thiastearoyl-ACP was a mixed-type inhibitor of 18:0-ACP, with an apparent K(I)

92 duct containing the exosite was a hyperbolic mixed-type inhibitor of ADAMTS13 proteolysis of either V

93 ATP is a mixed-type inhibitor of cGMP production for both sGC and

94 We also found verapamil to be a partial mixed-type inhibitor of chloroquine transport via PfCRT,

95 It is a mixed-type inhibitor of ETC with the kinetic constants,

96 vealed that A-183 was a partial (hyperbolic) mixed-type inhibitor of FX activation having a Ki of 200

97 containing tetrahedral mimic is a reversible mixed-type inhibitor of Gsp synthetase with an inhibitio

98 H2O2 is a mixed-type inhibitor of the dioxygenase activity, sugges

99 HX1 was a mixed-type inhibitor of the halogenation activity of MPO

100 o be an uncompetitive inhibitor to CoA and a mixed-type inhibitor to ATP and OSB with low micromolar

101 FAD behaved as a mixed-type inhibitor with respect to NADPH.

102 ha-pentagalloylglucose (alpha-PGG) acts as a mixed-type inhibitor.

103 ization revealed that the extract acted as a mixed-type inhibitor.

104 ith arachidonic acid indicated that it was a mixed-type inhibitor.

105 wave power levels (500, 1000 and 1500 W) are mixed type inhibitors of polyphenoloxidase enzyme, showi

106 Enzyme kinetics showed that 7 and 9 are mixed-type inhibitors of the binding of DNA primers and

107 ization studies identified these extracts as mixed-type inhibitors, effectively reducing both anodic

108 show at least one charge cluster, mostly of mixed type involving about equally anionic and cationic

109 Primary surveillance of mixed-type IPMN may be a reasonable strategy in select p

110 Among 674 patients with IPMNs, 202 had mixed-type IPMN, and 472 had BD-IPMN.

111 ents with MPD involvement, 238 patients with mixed-type IPMN, and 82 patients with main-duct IPMN alo

112 t primary surveillance, 70 for MPD-involved, mixed-type IPMN.

113 tation compared to branch duct (BD)-IPMN and mixed type-IPMN (OR 19.6, 95% CI 4.57-83.33, OR 16.3, 95

114 s and the co-occurrence of 2 or more HRMs in mixed-type IPMNs and BD-IPMNs.

115 edicting advanced neoplasia in patients with mixed-type IPMNs and should therefore be considered to h

116 This study found that mixed-type IPMNs are more likely to harbor HRMs associat

117 Overall, mixed-type IPMNs had significantly higher rates of HRMs

118 nal consensus that main-duct (MD) as well as mixed-type IPMNs should be treated surgically due to a h

119 Mixed-type IPMNs were defined as IPMNs with an MPD of 5

120 On multivariate logistic regression, mixed-type IPMNs were independently associated with HRMs

121 53, SMAD4, and MTOR mutations more common in mixed-type IPMNs.

122 of 86% for predicting advanced neoplasia in mixed-type IPMNs.

123 ical basis for higher malignant potential of mixed-type IPMNs.

124 mong invasive IPMNs, the majority (58%) were mixed-type lesions according to preoperative imaging.

125 MNs are misclassified as BD-IPMNs but reveal mixed-type lesions in histopathology.

126 DL is defined by the presence of >/=10 mixed-type lesions such as inflammatory papules and ulce

127 It is notable that several combinations of mixed types may appear in the clinical setting.

128 tumors, which included solid, papillary, and mixed types, may be associated with the cellular origin

129 13 (K(i) = 15.1 +/- 7.6 muM), which showed a mixed-type mechanism of inhibition.

130 activity of topoisomerase II by an unusual, mixed-type mechanism; the drug is not a competitive inhi

131 ed cell lineage tree under the Probabilistic Mixed-type Missing model, which we derive to describe ke

132 centrally to form a large BB (n = 5), and a mixed type (n = 3).

133 ements, that PLP inhibition is actually of a mixed-type nature and results from binding of this vitam

134 It was Mixed Type of Hyperbilirubinemia in gangrenous/perforate

135 Results showed a mixed type of inhibition behavior and, the docking molec

136 h dGTP, dGMP, whereas dTDP appears to have a mixed type of inhibition of dTMP kinase.

137 rans-anethole demonstrated noncompetitive to mixed type of inhibition of lens aldose reductase using

138 under varied PRPP and saturated pABA, and a mixed type of inhibition, K(1) = 0.60 mm and K(2) = 1.90

139 under varied PRPP and saturated pABA, and a mixed type of inhibition, K(1) = 1.40 mm and K = 3.800 m

140 tive inhibitor, while benzamidine presents a mixed type of inhibition.

141 However, PAR1-P40A displayed a mixed type of inhibition.

142 Small series, studies reporting on mixed types of cholangiocarcinoma, or exclusively on hep

143 cups, five [12%] cervical cups, and 11 [25%] mixed types of cups or unknown) and 15 were from low-inc

144 e new method is also applicable to data with mixed types of markers (dominant and codominant) with un

145 h consumed skim milk, and one-tenth consumed mixed types of milk.

146 pared to alternative strategies for modeling mixed types of nodes.

147 it pure pathology with most cases presenting mixed types of protein deposits in the brain.

148 methods are general: they can be applied to mixed types of traits, and to Z-statistics or P-values a

149 sue obtained from 26 patients in a cohort of mixed types of vascular malformation, comprising 2 fast-

150 026), depressed areas (P < .001), or nodular mixed type (P < .001) affected accuracy of identificatio

151 zymes AGAO and PPLO, pure noncompetitive and mixed-type/partially competitive inhibition is observed.

152 Azide was found to exhibit mixed-type/partially competitive inhibition with respect

153 er, EagleView supports viewing coassembly of mixed-type reads from different technologies and support

154 pid vesicles, characteristic of a hyperbolic mixed-type reversible inhibitor.

155 Kinetic studies showed that MB-gCs were mixed-type reversible inhibitors of both cholinesterases

156 The complexes also serve as mixed-type reversible inhibitors of human AChE and BuChE

157 (3) The ganglia-muscle mixed type: some individual varicose axons innervated bo

158 3.67; 95% CI: 1.33-10.11; p = 0.02) and with mixed-type tumors (aPR = 3.00; 95% CI: 1.70-5.30; p < 0.

159 was 5.8 % (95 % CI: 4.14, 7.53) (43/737) and mixed type VKC was the most frequent form which was foun

160 carcinoma (CCA), ampulla of Vater (AVC), and mixed type were matched to 5 controls on birth year, dia

161 d invasive adenocarcinoma and adenocarcinoma-mixed type with BAC features identified transcriptional

162 studies have shown that the inhibition is of mixed type with prominent (ca. 60 % of inhibition) uncom

163 6 microM and that H(2)O(2) inhibition is of mixed-type with respect to O(2).